Yahoo Finance

Rapid Medical™ Completes Enrollment in DISTALS Trial Evaluating TIGERTRIEVER 13™ for Distal Vessel Occlusions

SOUTHLAKE, Texas & YOKNEAM, Israel, December 09, 2025--(BUSINESS WIRE)--Rapid Medical™, a leading developer of active endovascular devices, announces the completion of patient enrollment in the ...
MarketWatch

Rapid Medical(TM)'s DISTALS Trial Overwhelmingly Positive, Demonstrating Superior Reperfusion with TIGERTRIEVER(TM) 13 in Medium Vessel Stroke

The MarketWatch News Department was not involved in the creation of this content. TIGERTRIEVER(TM) 13 is the first device shown to meet safety and effectiveness endpoints for restoring blood flow in ...
Morningstar

Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings

Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ...
Yahoo Finance

Rapid Medical™ Completes Enrollment in DISTALS Trial Evaluating TIGERTRIEVER 13™ for Distal Vessel Occlusions

The milestone reflects growing evidence for distal-specific thrombectomy solutions and is reinforced by interim findings that confirmed no safety concerns with TIGERTRIEVER 13. SOUTHLAKE, Texas & ...
Finanznachrichten

Rapid Medical Completes Enrollment in DISTALS Trial Evaluating TIGERTRIEVER 13 for Distal Vessel Occlusions

The milestone reflects growing evidence for distal-specific thrombectomy solutions and is reinforced by interim findings that confirmed no safety concerns with TIGERTRIEVER 13. Rapid Medical, a ...